LQCL2606 - CMLE - Novel Laboratory-Developed Test for Parkinson Disease Involving Kinetic Amyloid Amplification in Biofluid Specimens-LQCL2606

LQCL2606 - Educational Activity

Pdf Summary

This document is a Clinical Immunology LabQ module (2026, UCSF) using a case-based format to review Parkinson disease (PD) diagnosis and a novel laboratory-developed test (LDT) for detecting misfolded α-synuclein via seed amplification assay (SAA). A 62-year-old man presents with classic parkinsonian motor findings—progressive unilateral resting tremor, bradykinesia, cogwheel rigidity, shuffling gait, and decreased arm swing—along with prodromal non-motor symptoms (constipation and hyposmia). Brain MRI is unremarkable, while dopamine transporter PET shows reduced basal ganglia uptake; partial improvement with carbidopa-levodopa supports PD.<br /><br />The module summarizes PD epidemiology (common onset 60–70 years, male predominance, rising global burden, moderate survival reduction, high costs) and pathogenesis centered on prion-like misfolding and spread of α-synuclein, forming Lewy bodies/neurites. It highlights the Braak hypothesis that pathology may begin in the gut or olfactory bulb, propagate via the vagus nerve to the brainstem and substantia nigra, and later involve peripheral tissues—creating opportunities for biomarker testing in CSF, blood, skin, and other specimens.<br /><br />SAA is explained as an “amyloid PCR”: patient “seed” aggregates template recombinant α-synuclein fibril growth, with cycles of elongation and fragmentation producing exponential amplification. Thioflavin T fluorescence tracks fibril formation over time; interpretation relies on lag-time separation between positive and negative controls.<br /><br />Because SAAs are currently LDTs (not FDA-cleared), the module reviews CLIA-based validation expectations (accuracy, precision, reportable and reference ranges, sensitivity/LoD, specificity/interference) and notes added CAP and New York State requirements. The case troubleshooting focuses on failed control kinetics; root cause analysis identifies suboptimal storage of recombinant α-synuclein causing pre-formed aggregates, corrected by proper –80°C storage, restoring control discrimination and confirming PD in the patient, enabling trial enrollment.

Keywords

Parkinson disease diagnosis

alpha-synuclein misfolding

seed amplification assay (SAA)

laboratory-developed test (LDT)

Thioflavin T fluorescence kinetics

Lewy bodies and Lewy neurites

Braak hypothesis gut-olfactory origin

dopamine transporter PET imaging

CLIA CAP validation requirements

recombinant alpha-synuclein storage -80C